S1PR1 and COVID-19: In this regard, cocktails of immunomodulatory drugs, such as monoclonal antibody targeting a specific cytokine (e.g. TNF- inhibitors, IL-1-inhibitors, IL-6 inhibitors), corticosteroids (e.g. prednisone, methylprednisolone and dexamethasone), and S1PR1 agonists (e.g. fingolimod), rather than a single drug, might be more effective in the management of COVID-19, by exerting either synergic or additive effects.